Abstract
rTMS is approved by FDA for treatment of drug-resistant depression, and has been shown to be useful in cases where antidepressant treatment is complicated by intolerable side effects. The success rate of rTMS was reported to be above 70%. Improved gait speed and motor functioning have been recorded in patient with Parkinson’s disease (PD) when high frequency rTMS is delivered over the motor areas of the cortex. Index case was a 74-year old man with 6 years history of Depression and 1 year history of Parkinson’s disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Paper Title
Journal
Date
